Bill

Bill > H1137


MA H1137

MA H1137
Relative to cancer patient access to biomarker testing to provide appropriate therapy


summary

Introduced
03/29/2021
In Committee
03/30/2022
Crossed Over
Passed
Dead
12/31/2022

Introduced Session

192nd General Court

Bill Summary

Relative to insurance coverage for biomarker testing for certain cancer patients. Financial Services.

AI Summary

This bill aims to provide cancer patients with advanced or metastatic stage 3 or 4 cancer access to biomarker testing without the need for prior authorization. Biomarker testing is a diagnostic procedure that analyzes a patient's biospecimen, such as tissue, blood, or other bodily fluids, to identify DNA and/or RNA alterations that can help guide their treatment. The bill amends various chapters of the Massachusetts General Laws to prohibit insurance providers from requiring prior authorization for this type of testing for eligible cancer patients.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (8)

Last Action

Accompanied a study order, see H5222 (on 09/15/2022)

bill text


bill summary

Loading...

bill summary

Loading...

bill summary

Loading...